N4P.L Stock Analysis
N4
Uncovered
N4 Pharma PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 5 full-time employees. The company went IPO on 2005-06-07. The firm is focused on developing a silica nanoparticle delivery system, namely Nuvec for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. Nuvec is a non-viral adjuvant delivery system for vaccines and cancer treatments. This nanoparticle, Nuvec, has the potential to help commercialize cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Its Nuvec silica nanoparticles has an irregular (spiky) surface structure, coupled with polyethyleneimine (PEI), that effectively traps and protects nucleic acid, such as messenger ribonucleic acid (mRNA) as it travels to the cells. Its Nuvec generates predominantly a T Helper Cell Type 1 (Th1) response, characterized by an interferon gamma production, which leads to fight intracellular parasites, such as viruses or to kill cancer cells.